T2S Group's Initial Public Offering on the Casablanca Stock Exchange
In a significant development for the Moroccan financial landscape, T2S Group, a prominent medical technology company, has announced plans to raise approximately MAD1.1 billion (equivalent to $118 million) through its initial public offering (IPO) on the Casablanca Stock Exchange. The Moroccan Capital Market Authority has granted approval for the company to list its shares, marking the first IPO on the bourse for the year 2026. The share price has been set at MAD223, and the subscription period is scheduled from July 13 to 17, 2026. This offering will consist of MAD350 million generated from new shares and MAD750 million from existing shares, illustrating a robust interest in capital markets amidst a recovering economy.
Strategic Plans and Financial Performance
T2S Group, established in 1992, has shown impressive growth, generating revenues of MAD1.7 billion in 2025, with projections indicating a nearly 21 percent increase in revenue for the current year. The company’s net profit reached MAD211 million last year and is anticipated to rise to approximately MAD235 million in 2026. The proceeds from this IPO are earmarked for expanding T2S's operations both within Africa and internationally, signaling the company’s commitment to growth and innovation in the medical technology sector. Following this IPO, UK-based Trone Investment Holdings, which currently holds a 62 percent stake in T2S, will see its ownership diluted to 42 percent, while founder Abderraouf Sordo will maintain a 20 percent stake. Post-listing, the free-float of shares is expected to be around 23 percent, enhancing liquidity for investors on the Casablanca Stock Exchange. This move comes at a time when the exchange experienced three listings last year, valued at a total of MAD6 billion, despite a benchmark index decline of over 3 percent in the first half of this year.
As reported by agbi.com.
